Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
I. Hoof (Hørsholm, Denmark), M. Witten (Hørsholm, Denmark), T. Stranzl (Hørsholm, Denmark), S. Brand (Hørsholm, Denmark), M. Shamji (London, United Kingdom), E. Bateman (Cape Town, South Africa), E. Bleecker (Tucson, United States of America), P. Andersen (Hørsholm, Denmark)
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Session: Asthma clinical trials and real-life studies
Session type: E-poster
Number: 877
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Hoof (Hørsholm, Denmark), M. Witten (Hørsholm, Denmark), T. Stranzl (Hørsholm, Denmark), S. Brand (Hørsholm, Denmark), M. Shamji (London, United Kingdom), E. Bateman (Cape Town, South Africa), E. Bleecker (Tucson, United States of America), P. Andersen (Hørsholm, Denmark). Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma. 877
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006
Effect of house dust mite sublingual immunotherapy on airway inflammation and remodeling in allergic asthma with rhinitis Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases Year: 2019
Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002
Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005
Oral presentation: Early sources of IL-13 in house dust mite-induced neonatal allergic airways disease Source: Lung Science Conference 2013 - Early origins and mechanisms of chronic lung disease Year: 2013
Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Association between dust mite sensitisation and asthma severity Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010
Circulating platelets activity in patients sensitised to house dust mite suffering from persistent allergic rhinitis with or without asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 590s Year: 2005
Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Allergen exposure in nondog and nonhouse dust mite sensitized atopic asthmatic subjects; effect on bronchial reactivity Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
The effect of BCG treatment on the remodelling in the house dust mite induced allergic asthma in mice Source: Eur Respir J 2005; 26: Suppl. 49, 580s Year: 2005
OPURIT: O malizumab-p rotected u ltra r ush s pecific i mmunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Calcaratarin D attenuates house dust mite-induced allergic asthma Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Sensitisation to house dust mite: its association with bronchial hyperresponsiveness and lung function in asthmatic children Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009
Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006
Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006